Ongoing Securities Investigation into Anika Therapeutics, Inc. (ANIK) - Contact Levi & Korsinsky
Levi & Korsinsky has initiated an investigation into Anika Therapeutics, Inc. for potential violations of federal securities laws following the company's announcement of clinical trial results for Hyalofast. Despite showing improvements in patient outcomes, the trial did not meet its primary endpoints, leading to a 27% drop in Anika's stock price on July 30, 2025. The investigation aims to gather more information regarding these developments.
NEW YORK, NY / ACCESS Newswire / August 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Anika Therapeutics, Inc. ("Anika Therapeutics, Inc.") concerning possible violations of federal securities laws.
Anika issued a press release on July 30, 2025, "announc[ing] topline results from its U.S. pivotal clinical trial of Hyalofast, a resorbable, hyaluronic acid scaffold used in conjunction with autologous bone marrow aspirate concentrate (BMAC) for cartilage repair." The press release stated that "[w] hile Hyalofast demonstrated consistent improvements in treated patients across all measures of pain and function relative to microfracture, the study did not meet its pre-specified co-primary endpoints. The study was likely impacted by both a higher subject dropout rate in the microfracture arm and missed visits during COVID. This resulted in missing data, which reduced the evaluable sample size and complicated the statistical analysis."
Following this news, Anika's stock price fell over 27% on July 30, 2025. To obtain additional information, go to:
https://zlk.com/pslra-1/anika-therapeutics-inc-lawsuit-submission-form?prid=160674&wire=1&utm_campaign=50
or contact Joseph E. Levi, Esq.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
SOURCE: Levi & Korsinsky, LLP
View the original press release on ACCESS Newswire
